OPTN vs. INBX, OGI, MGNX, MDWD, PROC, IKT, ARTV, HURA, NLTX, and ZNTL
Should you be buying OptiNose stock or one of its competitors? The main competitors of OptiNose include Inhibrx (INBX), Organigram (OGI), MacroGenics (MGNX), MediWound (MDWD), Procaps Group (PROC), Inhibikase Therapeutics (IKT), Artiva Biotherapeutics (ARTV), TuHURA Biosciences (HURA), Neoleukin Therapeutics (NLTX), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical products" industry.
OptiNose vs.
OptiNose (NASDAQ:OPTN) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations, community ranking and media sentiment.
In the previous week, OptiNose had 8 more articles in the media than Inhibrx. MarketBeat recorded 9 mentions for OptiNose and 1 mentions for Inhibrx. Inhibrx's average media sentiment score of 0.00 beat OptiNose's score of -0.11 indicating that Inhibrx is being referred to more favorably in the news media.
OptiNose received 218 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 63.68% of users gave OptiNose an outperform vote while only 59.62% of users gave Inhibrx an outperform vote.
OptiNose currently has a consensus target price of $16.67, suggesting a potential upside of 140.85%. Given OptiNose's stronger consensus rating and higher possible upside, equities research analysts clearly believe OptiNose is more favorable than Inhibrx.
Inhibrx has a net margin of 0.00% compared to OptiNose's net margin of -41.16%. OptiNose's return on equity of 0.00% beat Inhibrx's return on equity.
OptiNose has higher revenue and earnings than Inhibrx.
85.6% of OptiNose shares are held by institutional investors. Comparatively, 82.5% of Inhibrx shares are held by institutional investors. 2.3% of OptiNose shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
OptiNose beats Inhibrx on 12 of the 15 factors compared between the two stocks.
Get OptiNose News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptiNose Competitors List
Related Companies and Tools
This page (NASDAQ:OPTN) was last updated on 1/21/2025 by MarketBeat.com Staff
